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ABSTRACT
Liver metastasis is the most frequent cause of death from colon and other 
cancers. Generally, liver metastasis is recalcitrant to treatment. The aim of this study 
is to determine the efficacy of tumor-targeting Salmonella typhimurium A1-R on liver 
metastasis in orthotopic mouse models. HT-29 human colon cancer cells expressing 
red fluorescent protein (RFP) were used in the present study. S. typhimurium A1-R 
infected HT-29 cells in a time-dependent manner, inhibiting cancer-cell proliferation 
in vitro. S. typhimurium A1-R promoted tumor necrosis and inhibited tumor growth 
in a subcutaneous tumor mouse model of HT-29-RFP. In orthotopic mouse models, 
S. typhimurium A1-R targeted liver metastases and significantly reduced their growth. 
The results of this study demonstrate the future clinical potential of S. typhimurium 
A1-R targeting of liver metastasis.
INTRODUCTION
Anecdotal records go back hundreds of years 
describing patients having their cancer go into remission 
after a bacterial infection [1]. In 1867, the German 
physician Busch reported that a cancer patient went 
into remission after contracting erysipelas, now known 
as Streptococcus pyogenes [2]. Bruns treated a cancer 
patient in 1888 with S. pyogenes and the tumor regressed 
[1]. Koch, Pasteur and von Behring recorded that 
cancer patients infected with S. pyogenes had tumor 
regression [1].
In the 1890s, William B. Coley of New York Cancer 
Hospital, which became Sloan-Kettering Memorial 
Cancer Center, treated cancer patients with S. pyogenes. 
Coley had excellent results infecting cancer patients with 
S. pyogenes. Hoption Cann et al. [3] compared Coley’s 
bacterial treatment to current chemotherapy and found the 
10-year survival rates of Coley’s patients were comparable 
[4] to current conventional therapies [4].
Malmgren and Flanigan [5] demonstrated that 
anaerobic bacteria could survive and replicate in necrotic 
tumor tissue which had low oxygen content. Several other 
early approaches aimed at utilizing bacteria for cancer 
therapy in animal models were described [6–16].
The obligate anaerobes Bifidobacterium [17] and 
Clostridium [18], which replicate only in necrotic areas 
of tumors, have been tested for cancer therapy in mouse 
models. Bifidobacterium longum selectively localized 
in mammary tumors after systemic administration [17]. 
Spores of Clostridium novyi, without its lethal toxin 
(C. novyi no toxin [NT]). germinated within necrotic areas 
of tumors in mice and, in combination with chemotherapy, 
resulted in hemorrhagic necrosis and tumors regression 
[18]. Recently, C. novyi-NT was used in a patient with 
leiomyosarcoma and caused one metastatic lesion to 
regress [19].
Salmonella typhimurium (S. typhimurium) is 
a facultative anaerobe which, in contrast to obligate 
anaerobes, can grow in the viable regions as well 
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as necrotic regions of tumors [20]. S. typhimurium 
with a lipid A—mutation (msbB) deletion along with 
purine auxotrophic mutations (purI) had antitumor 
efficacy in mice [21]. S. typhimurium (VNP20009), 
with msbB and purI mutations, was relatively safely 
administered to patients in a Phase I clinical trial on 
patients with metastatic melanoma and renal carcinoma. 
Overattenuation perhaps limited efficacy [22].
Liver metastases is the most frequent cause 
of death of patients with colorectal cancer [23]. 
Hepatectomy is the most effective treatment for liver 
metastasis from colorectal cancer, but the recurrence rate 
is over 50% after resection [24]. In addition, efficacy of 
chemotherapeutic agents are marginal [25]. Therefore, 
development of effective treatment for liver metastasis 
is urgently needed.
The tumor-targeting S. typhimurium A1-R strain 
developed by our laboratory has high tumor colonization 
and antitumor efficacy. S. typhimurium A1-R is auxotrophic 
for leu-arg, which prevents it from mounting a continuous 
infection in normal tissues. S. typhimurium A1-R was able 
to inhibit or eradicate primary and metastatic tumors as 
monotherapy in nude mouse models of prostate [26, 27], 
breast [28–30], lung [31, 32], pancreatic [33–37], ovarian 
[38, 39], stomach [40] and cervical cancer [41], as well 
as sarcoma [42–45] and glioma [46, 47], all of which are 
highly aggressive tumor models.
The present report demonstrates efficacy of 
S. typhimurium A1-R on liver metastasis of colon cancer 
in orthotopic mouse models.
RESULTS AND DISCUSSION
S. typhimurium A1-R targeted HT-29 colon 
cancer cells in vitro
S. typhimurium A1-R-GFP infection of HT-29 cells 
expressing red fluorescent protein (HT-29-RFP) was 
observed beginning 1 hour after addition of bacteria to the 
cultures (Figure 1A–1B). At 15 hours after addition, many 
S. typhimurium A1-R-GFP cells were observed inside the 
HT-29 cancer cells (Figure 1C).
S. typhimurium A1-R inhibited HT-29 cancer cell 
proliferation in vitro
HT-29-RFP cancer cell colonies were significantly 
reduced by S. typhimurium A1-R-GFP both in area 
(Figure 1D) and number (Figure 1E) (P < 0.01 for both).
Efficacy of S. typhimurium A1-R on 
subcutaneous HT-29 tumor growth
Subcutaneous tumor growth was significantly inhibited 
after the 3rd i.v. administration of S. typhimurium A1-R. The 
tumor volume ratio at day 22 compared to day 1 in the control 
group was 6.17 ± 1.16 and 2.68 ± 0.73 in the S. typhimurium 
A1-R treatment group, P < 0.05 (Figure 2A–2D). 
Resected specimens showed S. typhimurium A1-R induced 
more extensive necrosis in the tumors compared to those 
without treatment (Figure 2E–2H).
Efficacy of S. typhimurium A1-R on orthotopic 
liver metastasis mouse models
S. typhimurium A1-R-GFP targeted the liver metastasis 
3 days after the 2nd i.v. administration of S. typhimurium 
A1-R (Figure 3). S. typhimurium A1-R treatment 
significantly suppressed metastatic progression compared 
to the control group at day 22. The metastasis fluorescent 
area ratio on day 22 compared to day 1 was 5.69 ± 0.83 in 
the S. typhimurium A1-R treatment group and 12.96 ± 1.49, 
in the untreated control group (P < 0.01; Figure 4).
The present study demonstrated that tumor-targeting 
S. typhimurium A1-R has significant efficacy on liver 
metastasis in orthotopic mouse models, suggesting clinical 
activity for patients with colorectal liver metastasis. The 
present study suggests S. typhimurium A1-R may also 
be useful in the neo-adjuvant setting to reduce the liver 
metastasis that would make previously inoperable liver 
metastasis resectable.
Spleen injection selects colon cancer cells which 
can grow in the liver. However, this leads to multiple 
metastatic sites, which were harvested to directly implant 
a single metastases on the liver of additional mice, which 
was the desired model. Future experiments will treat 
models with multiple liver metastases with S. typhimurium 
A1-R.
This is the first study to use S. typhimurium A1-R 
to treat colon cancer liver metastasis, which occurs at 
high frequency and is usually the cause of lethality of this 
disease. The significant efficacy of S. typhimurium A1-R 
on the liver metastasis was comparable to the efficacy of 
S. typhimurium A1-R on other tumor types [26–47].
We have previously demonstrated efficacy of 
S. typhimurium A1-R in combination with anti-angiogenesis 
therapy in pancreatic cancer mouse models [37]. Future 
experiments will also test this combination in colon-cancer 
liver-metastasis models.
S. typhimurium A1-R in combination with 
chemotherapy was also active against stomach and 
pancreatic cancer models [35, 40]. Such strategies will 
also be tested on colon-cancer liver-metastasis in future 
experiments.
The present study used GFP and RFP to image 
S. typhimurium A1-R and the cancer cells, respectively, 
in vitro and in vivo. Genetic reporters have an important 
advantage over injectable probes in that the label is 
permanent with genetic reporters. This is important 
for long-term monitoring of bacterial targeting as 
well as tumor growth, including metastasis as well as 
recurrence [48].
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Bacteria have numerous advantages over other 
biological therapy in that bacteria actively invade 
tumors, even when vascularity is poor and have a large 
genome to manipulate for effective and selective tumor 
targeting [2].
Previously developed concepts and strategies 
of highly selective tumor targeting [49–53] can take 
advantage of bacterial targeting of tumors.
Tissue-selective therapy focuses on unique 
properties of normal tissues and how therapy can target a 
property of a tissue that kills the cancer tissues that arise 
from the normal tissue without affecting other tissues 
[49, 54]. S. typhimurium A1-R is an example of tissue-
selective therapy.
De-differentiation of a tumor leading to resistance 
to chemotherapy is a limitation of tissue-selective therapy, 
since the targeted protein or pathway may no longer be 
expressed in the de-differentiated tumor [54]. However, 
S. typhimurium A1-R does not seem to depend on such 
targets and should be active against de-differentiated 
tumors. Specific caspase inhibitors may protect 
normal cells which may not be present in drug-resistant 
cancer cells and those could provide further protection to 
normal cells during S. typhimurium A1-R therapy [49, 51]. 
S. typhimurium A1-R may also be effectively combined 
with teratogens which could selectively effect cancer 
cells that are de-differentiated [50]. Since S. typhimurium 
A1-R can decoy quiescent cancer cells to begin to cycle, 
S. typhimurium A1-R could be effectively combined with 
agents which selectively target proliferating cancer cells 
[52]. In this regard, normal cells could be protected by 
agents which induce wild type p53 [53].
Figure 1: In vitro efficacy of S. typhimurium A1-R-GFP on HT-29-RFP colon cancer cells. A–C. Confocal imaging of 
HT-29-RFP cells with S. typhimurium A1-R-GFP over time with the FV1000 confocal microscope. S. typhimurium A1-R infection of 
HT-29-RFP cells at one hour after administration (B) At 15 hour after administration, more bacterial cells were visualized in cancer cells 
(C). Arrows show infecting S. typhimurium A1-R expressing GFP. S. typhimurium A1-R inhibited cell proliferation both in colony area  
D. and number E. **P < 0.01. Error bars: ± 1 SE. Scale bars: 20 μm (BF, bright-field). The cells in Figures 1A, B and C were chosen as 
before and after examples of infection with S. typhimurium A1-R-GFP, not to indicate efficacy, which occurs at later times.
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MATERIALS AND METHODS
Cell line
The human colon cancer cell line HT-29 [55, 56] 
was maintained in DMEM (Irvine Scientific, Irvine, CA) 
supplemented with heat-inactivated 10% fetal bovine serum 
(FBS) (Gemini Biologic Products, Calabasas, CA), 2 mM 
glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, 
and 0.25 μg/ml amphotericin B (Life Technologies, Inc., 
Grand Island, NY). The cells were incubated at 37°C in 5% 
CO2. Expression of RFP indicated viability.
Establishment of RFP-labeled HT29
The pDsRed-2 vector (Clontech Laboratories Inc., 
Palo Alto, CA) expressing RFP and neomycin resistance 
gene were used to transfect HT-29 to stably express RFP. 
For RFP gene transfection, 25% confluent HT-29 cells 
were incubated with a mixture of retroviral supernatants 
of PT67-RFP packaging cells and DMEM for 24 h. Fresh 
medium was replenished at this time, and cells were 
allowed to grow in the absence of retrovirus for 12 h. 
This procedure was repeated until high levels of RFP 
expression were achieved. Cells were then harvested with 
trypsin-EDTA and subcultured into selective medium that 
contained 200 μg/ml G418 (Invitrogen Corp., Carlsbad, 
CA). The level of G418 was increased to 2, 000 μg/ml 
stepwise. HT-29 clones expressing high levels of RFP 
were isolated and were amplified and transferred using 
conventional culture methods. High RFP-expression 
clones were subsequently isolated in the absence of G418 
for 10 passages to select for stable expression of RFP 
[55, 57, 58].
Figure 2: Efficacy of S. typhimurium A1-R on HT-29-RFP subcutaneous tumor growth. Subcutaneous tumor models were 
established by injection of HT-29-RFP cells in the flanks of nude mice. A–C. Upper panels show bright-field images of tumor growth and 
lower show RFP images of tumor growth obtained with the OV-100 Small Animal Imaging System. An HT-29-RFP subcutaneous tumor 
in the right flank before treatment (day 1) (A), and after treatment with S. typhimurium A1-R at day 22 (B), HT-29-RFP tumor in the 
untreated control group at day-22 (C). D. S. typhimurium A1-R administration significantly decreased tumor volume at day-22 compared 
to no treatment. E–H. Representative histological images of excised tumors. S. typhimurium A1-R treated tumors had scattered necrosis 
surrounding viable cancer (E), (F). In contrast, untreated tumors had less necrosis (G), (H). (F) and (H) are high-magnification images of 
(E) and (G), respectively. *P < 0.05. Error bars: ± 1 SE. Arrows show necrotic areas. Scale bars: 20 mm (A) – (C), 500 μm (E) and (G), 
200 μm (F) and (H).
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Mice
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. All 
mouse surgical procedures and imaging were performed 
with the animals anesthetized by subcutaneous injection 
of a ketamine mixture (0.02 ml solution of 20 mg/kg 
ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg 
acepromazine maleate). All animal studies were conducted 
in accordance with the principles and procedures outlined 
Figure 3: Intravital imaging of tumor-targeting S. typhimurium A1-R in HT-29 liver metastasis. S. typhimurium A1-R-GFP 
was visualized in the HT-29-RFP liver metastases at day 11 (three days after the second administration of S. typhimurium A1-R-GFP). 
A. Liver metastases were visualized with the OV100. B–D. Confocal imaging with the FV1000 demonstrated S. typhimurium A1-R-GFP 
targeting the HT-29-RFP liver metastasis. Scale bars: 5 mm (A), and 50 μm (B)–(D).
Figure 4: Efficacy of S. typhimurium A1-R on HT-29-RFP liver metastasis. A, B. Upper panels are bright-field and lower 
panels are RFP images. Images of liver metastasis at day-22. No treatment (control group; A) and treated with S. typhimurium A1-R (S. 
typhimurium A1-R group; B). C. Bar graphs demonstrates the ratio of tumor fluorescent area at day 22 to day 1. Metastasis growth in the 
A1-R group was significantly inhibited compared to the untreated control group. **P < 0.01. Scale bars: 5 mm.
Oncotarget31373www.impactjournals.com/oncotarget
in the National Institutes of Health Guide for the Care and 
Use of Animals under Assurance Number A3873-1.
Preparation of S. typhimurium A1-R
GFP-expressing S. typhimurium A1-R bacteria 
(AntiCancer Inc.,) were grown overnight on LB 
medium (Fisher Sci., Hanover Park, IL, USA) and then 
diluted 1:10 in LB medium. Bacteria were harvested at 
late-log phase, washed with PBS, and then diluted in 
PBS [28].
Clonogenic assay
HT-29-RFP cells (2.0 × 102) were seeded in 35 mm 
dishes. S. typhimurium A1-R-GFP (5 × 105 CFU/ml) was 
added to the cancer cells, which were incubated at 37oC 
for 40 minutes. The cells were rinsed and cultured in 
medium containing gentamycin (10 μg/ml). After 9 days 
culture, the colonies were fixed with methanol and 
stained with crystal violet. The Image J program v1.49f 
(National Institutes of Health) was used to quantify the 
colonies.
Confocal imaging of cancer cells infected by 
S. typhimurium A1-R
HT-29-RFP cells (4.0 × 104) were seeded in 35 mm 
dishes. S. typhimurium A1-R-GFP (5 × 105 CFU/ml) was 
added to the cancer cells, which were incubated at 37oC for 
40 minutes. The cells were rinsed and cultured in medium 
containing gentamycin (10 μg/ml). The interaction 
between S. typhimurium A1-R expressing GFP and HT-29 
cancer cells expressing RFP was imaged in real time by 
confocal microscopy (Fluoview FV1000, Olympus Corp., 
Tokyo, japan) [59] before, and 1 hour and 15 hours after 
administration of S. typhimurium A1-R.
Efficacy of S. typhimurium A1-R on HT-29 
subcutaneous tumors
HT-29-RFP cells were harvested by trypsynization 
and washed with serum-free medium. A cell suspension 
(2 × 106 cells/100 μl in medium with 50% Matrigel) was 
injected subcutaneously in the right flank of nude mice. 
Two weeks after cell injection, established subcutaneous 
tumors were measured weekly and treated. Fourteen 
mice were randomized into a control group (n = 7) 
and an S. typhimurium A1-R treatment group (n = 7). 
The first treatment day was defined as day 1. Mice 
in the S. typhimurium A1-R group were treated with 
S. typhimurium A1-R (5 × 107 CFU/body) 3 times at days 
1, 8, and 15. All tumors in both groups were observed 
weekly with the OV100 Small Animal Imaging System 
(Olympus) [60] and harvested at day 22 for tissue 
evaluation. Each tumor was measured individually in each 
mouse. Tumor volume was calculated with the following 
formula: Tumor volume = 1/2 × Length × Width2. 
Treatment efficacy was presented as a ratio of the tumor 
volume at each time point compared to the tumor volume 
at the beginning of the treatment. Dosing was determined 
from efficacy in other tumor models of S. typhimurium 
A1-R [26–47].
Initial establishment of liver metastases
HT-29-RFP cells were harvested by trypsinization 
and washed twice with serum-free medium. HT-29-RFP 
cells (5 × 105 in 50 μl serum-free medium with 50% 
Matrigel) were injected into the superior and inferior pole 
of the spleen in nude mice. Three weeks after injection, 
liver metastases were established (Figure 5A).
Surgical orthotopic implantation of liver 
metastasis
Liver metastases, as described above, were resected 
and cut into block (8 mm3) (Figure 5B). A single tumor 
fragment was orthotopically implanted into the left lobe 
of the liver in other nude mice (Figure 5C). Four weeks 
later, liver metastasis were observed at the implanted site 
(Figure 5D).
Efficacy of S. typhimurium A1-R on liver 
metastasis
Four weeks after orthotopic implantation of HT- 
29-RFP to the liver, 10 mice were randomized into 
2 groups: untreated control group (weekly, 3 weeks, 
n = 5) and the S. typhimurium A1-R treatment group 
(S. typhimurium A1-R, 5 × 107 CFU/body, iv, weekly, 
3 weeks, n = 5). The left lobe of the liver with metastasis 
was exposed before (at day 1) and after treatment (at 
day 22) for observation with the OV100. The tumor 
fluorescence area was analyzed with ImageJ software. 
Treatment efficacy in each mouse was compared as a 
ratio of the tumor volume at each time point compared 
to the tumor volume at the beginning of treatment. Liver 
metastasis in the S. typhimurium A1-R treatment group 
was imaged with the FV1000 confocal microscope at 
day 11 to observe S. typhimurium A1-R-GFP targeting 
the RFP-expressing HT-29 liver metastasis.
Histology of tissue
Fresh tumor samples were fixed in formalin (10%) and 
embedded in paraffin before sectioning and staining. Tissue 
sections (3 mm) were deparaffinized in xylene and rehydrated 
in an ethanol series. Hematoxylin and eosin (H & E) staining 
was performed according to standard protocols.
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Statistical analysis
SPSS statistics version 21.0 was used for all statistical 
analyses (IBM, New York City, NY, USA). Significant 
differences for continuous variables were determined using 
the Mann-Whitney U test. Bar graphs expressed average 
values and error bar showed SE. A probability value of 
P ≤ 0.05 was considered statistically significant.
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